PARP inhibition in Prostate Cancer: Optimizing Care for Veterans

Get up to date on optimal Veterans Affairs care of patients receiving combination and single-agent PARP inhibitor regimens for prostate cancer with downloadable slides, an on-demand webcast, and expert commentary.

Share

Program Content

Activities

PARPi in Prostate Cancer Webcast
PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 05, 2024

Expires: April 04, 2025

Activities

PARPi for Prostate Cancer in Veterans
PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 31, 2024

Activities

PARPi for Prostate Cancer FAQ
PARP Inhibitors for Prostate Cancer: Expert Answers to Your Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 09, 2024

Expires: April 08, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA